Pipeline

Overview

Innovative pipeline development strategy

Differentiated R&D for Fast New Drug Success and Profitability

  • Pipeline
  • Indication
  • Route of
    Administration
  • Discovery
    Preclinical
    Phase Ⅰ

    Phase Ⅱ

    2a 2b

    Phase Ⅲ
    Launch
  • CU06
    Diabetic Macular Edema
    Oral

    Phase 2a study (us) began in Oct 2022
  • CU06
    Wet-AMD(Age-related Macular Degeneration)
    Oral

    Completed phase 1 study (US) in Jun 2022
  • CU101
    Myocardial Infarction
    Oral

    Completed phase 1 study (US) in Jun 2022(Oral)
  • CU102
    Acute Lung Injury
    Oral

    Completed phase 1 study (US) in Jun 2022
  • CU103
    Stroke
    Oral

    Completed phase 1 study (US) in Jun 2022(Oral)
  • CU104
    Ulcerative Colitis
    Oral

    Completed phase 1 study (US) in Jun 2022
  • CU105
    Hereditary Angioedema
    Oral

    Completed phase 1 study (US) in Jun 2022
  • CU106
    Immuno-Oncology Combination
    Oral

    Completed phase 1 study (US) in Jun 2022(Oral)
  • Pipeline
  • Indication
  • Route of
    Administration
  • Discovery
    Preclinical
    Phase Ⅰ

    Phase Ⅱ

    2a 2b

    Phase Ⅲ
    Launch
  • CU01
    Diabetic Nephropathy
    Oral

    Phase 2b first patient enrolled in Feb 2023
  • CU03
    Wet-AMD(Age-related Macular Degeneration)
    Oral

    Finalized phase 2 CSR in Jan 2022
  • CU04
    Cancer
    Oral

    Discovery
  • CU05
    Cancer
    Oral

    Discovery